SCHEMBL5190100

SCHEMBL5190100

CS(=O)(=O)c1ccc(Nc2ncnc(OCC3CCN(C(=O)O)C3)c2[N+](=O)[O-])cc1

nearest known ligand 0.55

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 20/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL389917 0.90 GPR119 (0.64) GPR119
SCHEMBL389360 0.86 GPR119 (0.68) GPR119
SCHEMBL3681418 0.84 GPR119 (0.65) GPR119
SCHEMBL3164609 0.83 GPR119 (0.58) GPR119
SCHEMBL3163892 0.81 GPR119 (0.61) GPR119
SCHEMBL5046374 0.81 GPR119 (0.54) GPR119
SCHEMBL387987 0.80 GPR119 (0.65) GPR119
SCHEMBL1070010 0.79 GPR119 (0.62) GPR119
SCHEMBL388590 0.78 GPR119 (0.64) GPR119
SCHEMBL389106 0.77 GPR119 (0.64) GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1758565-A2 COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL Arena Pharmaceuticals, Inc. (US) 2007-03-07 EP disclosed
WO-2006076231-A2 COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL ARENA PHARMACEUTICALS, INC. (US) 2006-07-20 WO disclosed